Neurology Minute

Dr. Jason Crowell and Dr. Colin Hoy discuss the concept of prodromal Parkinson disease and the ethical considerations surrounding its diagnosis. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209522

Dr. Jeff Ratliff, a medical professional specializing in movement disorders, dives deep into emergent rigidity and movement difficulties. He emphasizes the importance of thorough patient assessment and reviews critical medication histories. The discussion highlights serious complications like neuroleptic malignant syndrome and serotonin syndrome, advocating for both supportive care and necessary medication adjustments. Dr. Ratliff’s insights provide essential strategies for managing these complex emergencies effectively.

In the second episode of this three-part series, Dr. Jeff Ratliff provides a rapid overview of hyperkinetic disorders that require urgent attention.

Dr. Jeff Ratliff, a specialist in movement disorder emergencies, dives into the critical realm of rapid recognition and treatment. He emphasizes the importance of early diagnosis in clinical settings, highlighting the challenges practitioners face. The discussion covers essential considerations such as medication usage, relevant lab tests, and necessary imaging to ensure appropriate evaluation. This insightful conversation sets the stage for a deeper understanding of managing these urgent conditions.

Dr. Halley Alexander and Dr. Kimford Meador discuss perinatal exposure to anti-seizure medications and its effects on creativity and executive function in children. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209448

Dr. Matthew Barrett and Dr. Michael S. Okun discuss the caution and deliberation needed in understanding Parkinson disease biomarkers. Show reference: https://jamanetwork.com/journals/jamaneurology/article-abstract/2820441

In the final episode of this two-part series, Dr. Joe Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized myasthenia gravis. In this episode, he will talk about two of the treatment medications: Ravulizumab + zilucoplan. Show references: https://doi.org/10.1016/s1474-4422(21)00159-9 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00077-7/abstract

In the final part of this two-part series, Dr. Andy Southerland and Dr. Lidia Moura discuss strategies on how clinicians can mitigate bias when using large language models. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209497

Dr. Justin Abbatemarco, Dr. Michael R. Wilson, and Dr. John Pluvinage discuss their discovery of anti-CD320 antibodies in patients with neurologic manifestations of B12 deficiency and discuss the potential implications for diagnosis and treatment. Show reference: https://www.science.org/doi/10.1126/scitranslmed.adl3758

In part one of the part-two series, Dr. Andy Southerland and Dr. Lidia Moura discuss the major findings related to large language models (LLMs) for neurologic care. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209497